Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13899776 | 0.88 | PAOX (0.36) | PAOXSIGMAR1ALDH1A1MEN1RAD52 | |
| SCHEMBL13899774 | 0.86 | HRH3 (0.43) | SIGMAR1MAPT | |
| SCHEMBL6039721 | 0.81 | ALDH1A1 (0.44) | SIGMAR1ALDH1A1MAPTKDM1A | |
| SCHEMBL20332905 | 0.79 | PAOX (0.45) | PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL7029723 | 0.77 | ALOX15 (0.46) | PAOXSIGMAR1ALDH1A1CSNK2A2CSNK2B | |
| SCHEMBL19324186 | 0.74 | PAOX (0.43) | PAOXSIGMAR1ALDH1A1CSNK2A2CSNK2B | |
| SCHEMBL21634183 | 0.74 | SIGMAR1 (0.45) | PAOXSIGMAR1 | |
| SCHEMBL20332960 | 0.74 | PAOX (0.41) | PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6600771 | 0.74 | SMN1; SMN2 (0.45) | SIGMAR1ALDH1A1MAPT | |
| SCHEMBL15340822 | 0.74 | PAOX (0.41) | PAOXSIGMAR1ALDH1A1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504399-B2 | Piperazine enamines as antiviral agents | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070287712-A1 | Piperazine Enamines as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287712-A1 | Piperazine Enamines as Antiviral Agents | INMT, ITPA, IDO1 | PAOX 3670/4885SIGMAR1 779/4885ALDH1A1 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.